Sartorius AG has signed a definitive agreement with Stedim Biosystems S.A., to acquire a substantial stake in Stedim, combining its Biotechnology Division with Stedim’s biopharmaceutical supply business. Upon completion of this transaction, Sartorius will become Stedim’s majority owner controlling the combined company. Further details of the transaction were not disclosed.  With the combination of the two businesses, Sartorius strengthens its position as a technology provider to...